RGLS ערך שוק Regulus

The confirmed price history on the Regulus Therapeutics (RGLS) chart demonstrates metrics at the level of 0.55. Regulus Therapeutics focuses on developing RNA therapies for renal pathologies, where financial stability depends directly on medical test outcomes. The business relies on independent chemical supply channels to sustain profits and is implementing automated microRNA analysis stations to accelerate the development of new drugs.

Market capitalization reflects the aggregate value of all shares, defining the current scale of the business through the lens of exchange demand. By analyzing the dynamics of the company's capitalization size, an investor tracks the balance between market expectations and actual liquidity. The metric is calculated as the product of the price of a single share and the total number of issued securities. For Regulus Therapeutics (RGLS), this metric serves as an indicator of market confidence in the success of RNA therapy. The absence of operating profit makes the valuation entirely dependent on clinical trial results.